I am thinking by end of August, Purple.Will be likely done at...

I am thinking by end of August, Purple.

Will be likely done at sub $20, be a nice surprise to not see this eventuate at that level.

It comes to a point where even though the last three CRs have been done at higher levels and a sp from $3 or so to the current level that it needs to move to the next level; the former is likely to the end that run, and the latter, the sp, down from a high of $28 or so not that long ago.

Sentiment for this stock is, arguably, negative, despite the ‘ability’ of the Company to raise funds and despite a number of positive announcements over time.

Couple of other things that may be inhibiting the sp is that the R&D spend is no where near where it should be, the Company virtually spinning its wheels in the interim, the second being the ‘end’ date from 2025 to 2028 for commercialisation.

Way too many options being generated, despite a ‘commitment’ to keep dilution to a minimum, that’s a huge reserve to sell into future milestones, inhibit the sp and repeat cycle.

The $15 CR had no options in the wings, why can the Company not sell a CR without the option addition?, for something the Company touts as having an internal valuation of $40 plus and a figure of one billion plus not being enough to buy this company.

That the Company can not sell at a premium and must offer a discount and throw in options is not a ideal position to be in, yes the sp does drift down, as it should because the stock has been diluted.

Honeymoon period will end at some time if the Company cannot deliver the WP spiel of $40 internal valuation being reflected in the sp and the Company knocking back that ‘one billion dollar’ plus deal.

One more CR at below $24 bearable, options attached ….. less so, from there onwards, late 2023 plus, the Company should be showing some lasting traction, if not may need to explain why not.

Imho, not advice.